The patients will share 800,000 kroner ($123,000), with the possibility of higher payouts depending on long-term impacts, such as work limitations. This decision comes after over 40 individuals filed claims citing non-arteritic anterior ischemic optic neuropathy (NAION)—a condition that reduces blood flow to the optic nerve and can cause permanent vision loss.
The Danish Patient Compensation Association noted that assessing these cases was complex, as the medications are relatively new and affected patients often had pre-existing risk factors for NAION. “NAION is a severe condition that can cause irreversible vision damage,” said Karen-Inger Bast, director of the association.
In response, Novo Nordisk, the manufacturer of both drugs, stated that patient information leaflets for all semaglutide-based products now list NAION as a “very rare” side effect, while emphasizing that the drugs’ overall benefit-risk balance remains positive.
According to the European Pharmacovigilance Risk Assessment Committee (PRAC), NAION occurs in up to 1 in 10,000 users, confirming its classification as a very rare side effect.
#Wegovy #Ozempic #NAION #HealthNews #VisionLoss #NovoNordisk #MedicalCompensation
